دورية أكاديمية
أعرض في EDS

Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations.

التفاصيل البيبلوغرافية
العنوان: Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations.
المؤلفون: Passamonti F; Department of Medicine and Surgery, University of Insubria, Varese, Italy.; Hematology, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy., Nicastri E; National Institute of Infectious Diseases 'L. Spallanzani', IRCCS, Roma, Italy., Di Rocco A; Department of Cellular Biotechnologies and Hematology, Hematology Unit, Sapienza University, Roma, Italy., Guarini A; Hematology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Ibatici A; Hematology Unit and Bone Marrow Transplantation, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Luminari S; Hematology Unit, Azienda Unità Sanitaria Locale, IRCCS Reggio Emilia, Reggio Emilia, Italy.; Dipartimento CHIMOMO, Università di Modena e Reggio Emilia, Reggio Emilia, Italy., Mikulska M; IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy., Visco C; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
المصدر: Hematological oncology [Hematol Oncol] 2023 Feb; Vol. 41 (1), pp. 3-15. Date of Electronic Publication: 2022 Oct 25.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford, England : Wiley-Blackwell, c1983-
مواضيع طبية MeSH: COVID-19* , Lymphoma*/drug therapy, Humans ; SARS-CoV-2 ; COVID-19 Vaccines ; Antiviral Agents/therapeutic use ; Antibodies, Monoclonal
مستخلص: Patients with hematologic malignancies can be immunocompromized because of their disease, anti-cancer therapy, and concomitant immunosuppressive treatment. Furthermore, these patients are usually older than 60 years and have comorbidities. For all these reasons they are highly vulnerable to infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and have an increased risk of developing severe/critical Coronavirus disease 2019 (COVID-19) compared to the general population. Although COVID-19 vaccination has proven effective in reducing the incidence of severe/critical disease, vaccinated patients with lymphoma may not be protected as they often fail to develop a sufficient antiviral immune response. There is therefore an urgent need to address the management of patients with lymphoma and COVID-19 in the setting of the ongoing pandemic. Passive immunization with monoclonal antibodies against SARS-CoV-2 is a currently available complementary drug strategy to active vaccination for lymphoma patients, while monoclonal antibodies and antiviral drugs (remdesivir, ritonavir-boosted nirmatrelvir, and molnupiravir) have proven effective in preventing the progression to severe/critical COVID-19. In this narrative review we present the most recent data documenting the characteristics and outcomes of patients with concomitant lymphoma and COVID-19. Our ultimate goal is to provide practice-oriented guidance in the management of these vulnerable patients from diagnosis to treatment and follow-up of lymphoma. To this purpose, we will first provide an overview of the main data concerning prognostic factors and fatality rate of lymphoma patients who develop COVID-19; the outcomes of COVID-19 vaccination will also be addressed. We will then discuss current COVID-19 prophylaxis and treatment options for lymphoma patients. Finally, based on the literature and our multidisciplinary experience, we will summarize a set of indications on how to manage patients with lymphoma according to COVID-19 exposure, level of disease severity and former history of infection, as typically encountered in clinical practice.
(© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
References: WHO. Living Guidance for Clinical Management of COVID-19. Accessed 15 July 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. https://doi.org/10.1038/s41586-020-2521-4.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337. https://doi.org/10.1016/S1470-2045(20)30096-6.
He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637-1645. https://doi.org/10.1038/s41375-020-0836-7.
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. https://doi.org/10.1016/S0140-6736(20)31187-9.
Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e745. https://doi.org/10.1016/S2352-3026(20)30251-9.
Yigenoglu TN, Ata N, Altuntas F, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93(2):1099-1104. https://doi.org/10.1002/jmv.26404.
Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32(6):787-800. https://doi.org/10.1016/j.annonc.2021.02.024.
Russell B, Moss CL, Shah V, et al. Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. Br J Cancer. 2021;125(7):939-947. https://doi.org/10.1038/s41416-021-01500-z.
Wang Q, Berger NA, Xu R. When hematologic malignancies meet COVID-19 in the United States: infections, death and disparities. Blood Rev. 2021;47:100775. https://doi.org/10.1016/j.blre.2020.100775.
El-Sharkawi D, Iyengar S. Haematological cancers and the risk of severe COVID-19: exploration and critical evaluation of the evidence to date. Br J Haematol. 2020;190(3):336-345. https://doi.org/10.1111/bjh.16956.
Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309-1316. https://doi.org/10.1016/S1470-2045(20)30442-3.
Nicastro E, Verdoni L, Bettini LR, et al. COVID-19 in immunosuppressed children. Front Pediatr. 2021;9:629240. https://doi.org/10.3389/fped.2021.629240.
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892. https://doi.org/10.1182/blood.2020008824.
Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298-310. https://doi.org/10.1016/S0140-6736(16)32407-2.
Lewis WD, Lilly S, Jones KL. Lymphoma: diagnosis and treatment. Am Fam Physician. 2020;101(1):34-41.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. https://doi.org/10.1056/NEJMoa2034577.
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. https://doi.org/10.1056/NEJMoa2035389.
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. https://doi.org/10.1016/S0140-6736(20)32661-1.
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med. 2021;384(23):2187-2201. https://doi.org/10.1056/NEJMoa2101544.
Fendler A, de Vries EGE, GeurtsvanKessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19(6):385-401. https://doi.org/10.1038/s41571-022-00610-8.
Sun C, Pleyer C, Wiestner A. COVID-19 vaccines for patients with haematological conditions. Lancet Haematol. 2021;8(5):e312-e314. https://doi.org/10.1016/S2352-3026(21)00073-9.
Gurion R, Rozovski U, Itchaki G, et al. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2022;107(3):715-720. https://doi.org/10.3324/haematol.2021.279216.
Buske C, Dreyling M, Alvarez-Larran A, et al. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022;7(2):100403. https://doi.org/10.1016/j.esmoop.2022.100403.
Shapiro AE, Bender Ignacio RA. Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19. Lancet Infect Dis. 2022;22(5):567-569. https://doi.org/10.1016/S1473-3099(21)00762-3.
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941-1950. https://doi.org/10.1056/NEJMoa2107934.
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236-1246. https://doi.org/10.1001/jama.2022.2832.
Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384(3):238-251. https://doi.org/10.1056/NEJMoa2035002.
Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N Engl J Med. 2021;384(3):229-237. https://doi.org/10.1056/NEJMoa2029849.
Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of covid-19. N Engl J Med. 2022;386(23):2188-2200. https://doi.org/10.1056/NEJMoa2116620.
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022;386(4):305-315. https://doi.org/10.1056/NEJMoa2116846.
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397-1408. https://doi.org/10.1056/NEJMoa2118542.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509-520. https://doi.org/10.1056/NEJMoa2116044.
Salvini M, Damonte C, Mortara L, et al. Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients. Am J Hematol. 2022;97(8):E321-E324. https://doi.org/10.1002/ajh.26629.
Lamure S, Dulery R, Di Blasi R, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study. EClinicalMedicine. 2020;27:100549. https://doi.org/10.1016/j.eclinm.2020.100549.
Regalado-Artamendi I, Jimenez-Ubieto A, Hernandez-Rivas JA, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere. 2021;5(3):e538. https://doi.org/10.1097/HS9.0000000000000538.
Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6(1):327-338. https://doi.org/10.1182/bloodadvances.2021005691.
Bonuomo V, Ferrarini I, Dell'Eva M, Sbisa E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: a review. World J Virol. 2021;10(6):312-325. https://doi.org/10.5501/wjv.v10.i6.312.
Garcia-Suarez J, de la Cruz J, Cedillo A, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133. https://doi.org/10.1186/s13045-020-00970-7.
Dulery R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934-944. https://doi.org/10.1002/ajh.26209.
Pagano L, Salmanton-Garcia J, Marchesi F, EPICOVIDEHA working group, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. https://doi.org/10.1186/s13045-021-01177-0.
Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol. 2021;195(3):371-377. https://doi.org/10.1111/bjh.17704.
Schmidt AL, Labaki C, Hsu CY, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2022;33(3):340-346. https://doi.org/10.1016/j.annonc.2021.12.006.
Heudel P, Favier B, Solodky ML, et al. Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients. Eur J Cancer. 2022;165:174-183. https://doi.org/10.1016/j.ejca.2022.01.035.
Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022;139(10):1588-1592. https://doi.org/10.1182/blood.2021014124.
Pinato DJ, Tabernero J, Bower M, et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021;22(12):1669-1680. https://doi.org/10.1016/S1470-2045(21)00573-8.
Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5(12):2624-2643. https://doi.org/10.1182/bloodadvances.2021004629.
Peeters M, Verbruggen L, Teuwen L, et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open. 2021;6(5):100274. https://doi.org/10.1016/j.esmoop.2021.100274.
Perry C, Luttwak E, Balaban R, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5(16):3053-3061. https://doi.org/10.1182/bloodadvances.2021005094.
Jurgens EM, Ketas TJ, Zhao Z, et al. Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am J Hematol. 2021;96(11):E410-E413. https://doi.org/10.1002/ajh.26322.
Lim SH, Campbell N, Johnson M, et al. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol. 2021;8(8):e542-e544. https://doi.org/10.1016/S2352-3026(21)00199-X.
Diefenbach C, Caro J, Koide A, et al. Impaired humoral immunity to SARS-CoV-2 vaccination in non-hodgkin lymphoma and CLL patients. medRxiv. 2021. https://doi.org/10.1101/2021.06.02.21257804.
Liebers N, Speer C, Benning L, et al. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 2022;139(1):142-147. https://doi.org/10.1182/blood.2021013445.
Sakuraba A, Luna A, Micic D. Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. J Hematol Oncol. 2022;15(1):15. https://doi.org/10.1186/s13045-022-01233-3.
Gagelmann N, Passamonti F, Wolschke C, et al. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis. Haematologica. 2022;107(8):1840-1849. https://doi.org/10.3324/haematol.2021.280163.
Jimenez M, Roldan E, Fernandez-Naval C, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022;6(3):774-784. https://doi.org/10.1182/bloodadvances.2021006101.
Shapiro LC, Thakkar A, Campbell ST, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022;40(1):3-5. https://doi.org/10.1016/j.ccell.2021.11.006.
Fendler A, Shepherd STC, Au L, et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2022;40(2):114-116. https://doi.org/10.1016/j.ccell.2021.12.013.
Greenberger LMLAS, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL, Nichols GL. Sars-Cov-2 antibody levels in blood cancer patients after a third sars-cov-2 “booster” vaccination - observational data from the LLS national registry. Blood. 2021;138(Suppl 1):185. Oral Abstract. 63rd ASH Annual Meeting Abstract. https://doi.org/10.1182/blood-2021-151419.
Gressens SB, Fourati S, Le Bouter A, et al. Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies. Clin Microbiol Infect. 2022;28(6):885.e7-885.e11. https://doi.org/10.1016/j.cmi.2022.02.029.
Fendler A, Shepherd STC, Au L, et al. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet. 2022;399(10328):905-907. https://doi.org/10.1016/S0140-6736(22)00147-7.
EMA. COVID-19: Joint Statement from ECDC and EMA on the Administration of a Fourth Dose of mRNA Vaccines. Accessed 18 July 2022. https://bit.ly/3PAQznN.
Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for covid-19 with convalescent plasma. N Engl J Med. 2022;386(18):1700-1711. https://doi.org/10.1056/NEJMoa2119657.
EMA. Casirivimab-imdevimab SPC. Accessed 18 July 2022. https://bit.ly/3IOAHw3.
EMA. Tixagevimab-cilgavimab SPC. Accessed 18 July 2022. https://bit.ly/3PH8JEJ.
EMA. Bamlanivimab-etesevimab SPC. Accessed 18 July 2022. https://bit.ly/3Ohg8tb.
EMA. Sotrovimab SPC. Accessed 18 July 2022. https://bit.ly/3Ohc9wA.
Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with covid-19. N Engl J Med. 2021;385(23):e81. https://doi.org/10.1056/NEJMoa2108163.
AIFA. Inserimento del medicinale «Evusheld» (associazione di anticorpi monoclonali tixagevimab e cilgavimab) nell'elenco dei medicinali ai sensi della legge 23 dicembre 1996, n. 648. (Determina n. DG/344/2022). Accessed 26 September 2022. https://www.aifa.gov.it/documents/20142/961234/Determina_DG-344-2022_Evusheld.pdf.
EMA. EMA Recommends Authorisation of COVID-19 Medicine Evusheld. Accessed 26 September 2022. https://www.ema.europa.eu/en/news/ema-recommends-authorisation-covid-19-medicine-evusheld.
Stuver R, Shah GL, Korde NS, et al. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022;40(6):590-591. https://doi.org/10.1016/j.ccell.2022.05.007.
FDA. FDA Authorizes Revisions to Evusheld Dosing. Accessed 18 July 2022. https://bit.ly/3Ph2MhR.
Group AC--TfIwC- S, Paredes R, Murray TA, et al. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022;10(10):972-984. https://doi.org/10.1016/S2213-2600(22)00215-6.
Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985-996. https://doi.org/10.1016/S2213-2600(22)00180-1.
Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against covid-19 omicron variant. N Engl J Med. 2022;386(10):995-998. https://doi.org/10.1056/NEJMc2119407.
FDA. Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity against Omicron Variant. Accessed 18 July 2022. https://bit.ly/3AVmKKJ.
EMA. Remdesivir SPC. Accessed 16 July 2022. https://bit.ly/3Pk203t.
EMA. Ritonavir and PF-07321332 SPC. Accessed 18 July 2022. https://bit.ly/3yKsDHU.
FDA. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. Accessed 18 July 2022. https://bit.ly/3ocGYbh.
AIFA. Definizione delle modalita' e delle condizioni di impiego dell'antivirale «Lagevrio» (molnupiravir). (Determina n. DG/1644/2021). (21A07770) (GU Serie Generale n.308 del 29-12-2021). Accessed 26 September 2022. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2021-12-29%26atto.codiceRedazionale=21A07770%26elenco30giorni=false.
ECDC. Treatment and Pharmaceutical Prophylaxis of COVID-19. Accessed 29 September 2022. https://www.ecdc.europa.eu/en/covid-19/latest-evidence/treatment.
EMA. Lagevrio (Molnupiravir) SPC. Accessed 18 July 2022. https://bit.ly/3uXFW6E.
Antonelli G, Focosi D, Turriziani O, et al. Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation. Clin Microbiol Infect. 2022:S1198-743X(22)00344-5. https://doi.org/10.1016/j.cmi.2022.06.029.
Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med. 2022;386(15):1475-1477. https://doi.org/10.1056/NEJMc2201933.
Service RF.A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm. Science. 2021. https://doi.org/10.1126/science.acx9591.
Società Italiana di Ematologia (SIE) e del Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Vaccinazione per COVID-19 nei pazienti con malattie del sangue e sottoposti a trapianto di cellule staminali. Accessed 18 July 2022. https://www.siematologia.it/storage/siematologia/article/pdf/22/2-documento-sie-gitmo_20210210-124518.pdf.
NIH. Testing for SARS-CoV-2 Infection. Summary Reccomendation. Accessed 18 July 2022. https://www.covid19treatmentguidelines.nih.gov/overview/sars-cov-2-testing/.
WHO. Living Guidance for Clinical Management of COVID-19. Accessed 18 July 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.
NIH. COVID-19 Treatment Guidelines. Clinical Management Summary. Accessed 18 July 2022. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/.
NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Accessed 16 July 2022. https://www.covid19treatmentguidelines.nih.gov/.
D'Abramo A, Vita S, Maffongelli G, et al. Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-COV-2 infection: defining a treatment pathway. Front Immunol. 2022;13:911339. https://doi.org/10.3389/fimmu.2022.911339.
فهرسة مساهمة: Keywords: COVID-19; SARS-CoV-2; antiviral; immunosuppression; lymphoma; monoclonal antibody
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (Antiviral Agents)
0 (Antibodies, Monoclonal)
تواريخ الأحداث: Date Created: 20221017 Date Completed: 20230202 Latest Revision: 20230202
رمز التحديث: 20230202
مُعرف محوري في PubMed: PMC9874581
DOI: 10.1002/hon.3086
PMID: 36251481
قاعدة البيانات: MEDLINE
الوصف
تدمد:1099-1069
DOI:10.1002/hon.3086